Your browser doesn't support javascript.
loading
An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
Suh, Jee Su; Minuzzi, Luciano; Raamana, Pradeep Reddy; Davis, Andrew; Hall, Geoffrey B; Harris, Jacqueline; Hassel, Stefanie; Zamyadi, Mojdeh; Arnott, Stephen R; Alders, Gésine L; Sassi, Roberto B; Milev, Roumen; Lam, Raymond W; MacQueen, Glenda M; Strother, Stephen C; Kennedy, Sidney H; Frey, Benicio N.
Afiliação
  • Suh JS; Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada; Mood Disorders Program and Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
  • Minuzzi L; Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada; Mood Disorders Program and Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
  • Raamana PR; Rotman Research Institute, Baycrest Health Sciences; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Davis A; Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, ON, Canada.
  • Hall GB; Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, ON, Canada.
  • Harris J; Department of Computing Science, University of Alberta, Edmonton, AB, Canada.
  • Hassel S; Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, AB, Canada.
  • Zamyadi M; Rotman Research Institute, Baycrest Health Sciences; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Arnott SR; Rotman Research Institute, Baycrest Health Sciences; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Alders GL; Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada; Mood Disorders Program and Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
  • Sassi RB; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
  • Milev R; Departments of Psychiatry and Psychology, Queen's University and Providence Care Hospital, Kingston, ON, Canada.
  • Lam RW; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • MacQueen GM; Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, AB, Canada.
  • Strother SC; Rotman Research Institute, Baycrest Health Sciences; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Kennedy SH; Canadian Biomarker Integration Network for Depression, St. Michael's Hospital, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Frey BN; Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada; Mood Disorders Program and Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada. Electronic a
Neuroimage Clin ; 25: 102178, 2020.
Article em En | MEDLINE | ID: mdl-32036277
Major depressive disorder (MDD) is considered a highly heterogeneous clinical and neurobiological mental disorder. We employed a novel layered treatment design to investigate whether cortical thickness features at baseline differentiated treatment responders from non-responders after 8 and 16 weeks of a standardized sequential antidepressant treatment. Secondary analyses examined baseline differences between MDD and controls as a replication analysis and longitudinal changes in thickness after 8 weeks of escitalopram treatment. 181 MDD and 95 healthy comparison (HC) participants were studied. After 8 weeks of escitalopram treatment (10-20 mg/d, flexible dosage), responders (>50% decrease in Montgomery-Åsberg Depression Scale score) were continued on escitalopram; non-responders received adjunctive aripiprazole (2-10 mg/d, flexible dosage). MDD participants were classified into subgroups according to their response profiles at weeks 8 and 16. Baseline group differences in cortical thickness were analyzed with FreeSurfer between HC and MDD groups as well as between response groups. Two-stage longitudinal processing was used to investigate 8-week escitalopram treatment-related changes in cortical thickness. Compared to HC, the MDD group exhibited thinner cortex in the left rostral middle frontal cortex [MNI(X,Y,Z=-29,9,54.5,-7.7); CWP=0.0002]. No baseline differences in cortical thickness were observed between responders and non-responders based on week-8 or week-16 response profile. No changes in cortical thickness was observed after 8 weeks of escitalopram monotherapy. In a two-step 16-week sequential clinical trial we found that baseline cortical thickness does not appear to be associated to clinical response to pharmacotherapy at 8 or 16 weeks.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Citalopram / Córtex Cerebral / Transtorno Depressivo Maior / Neuroimagem / Aripiprazol / Antidepressivos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neuroimage Clin Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Citalopram / Córtex Cerebral / Transtorno Depressivo Maior / Neuroimagem / Aripiprazol / Antidepressivos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neuroimage Clin Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá